Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immunoglobulin
100%
Guillain-Barré Syndrome
100%
Therapeutic Monoclonal Antibody
100%
Placebo-controlled
66%
Intravenous Immunoglobulin (IVIg)
66%
Phase II Trial
66%
Immunoglobulin G
33%
Monoclonal Antibody
33%
Complement Cascade
33%
Second Dose
33%
High Risk
33%
Adult Subjects
33%
Mechanism of Action
33%
High Dose
33%
Randomized Controlled Trial
33%
G-levels
33%
Recovery Time
33%
Autoimmune
33%
Pharmacokinetic Study
33%
Complement Proteins
33%
Randomized Double-blind
33%
Humanized
33%
Improved Outcomes
33%
Poor Prognosis
33%
Limb muscles
33%
Disability Status
33%
Plasma Exchange
33%
Polyradiculoneuropathy
33%
Facial Weakness
33%
Respiratory Function
33%
Distal Limb
33%
Supportive Care
33%
Late Effects
33%
Recombinant Antibody
33%
Eculizumab
33%
Cranial Nerves
33%
Therapeutic Plasma Exchange
33%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin
100%
Syndrome
100%
Monoclonal Antibody
100%
Immunoglobulin Antibody
100%
Weakness
66%
Placebo
66%
Complement Component C1q
33%
Pharmacokinetics
33%
Randomized Controlled Trial
33%
Thromboembolism
33%
Polyradiculoneuropathy
33%
Immunoglobulin G
33%
Side Effect
33%
Recombinant Antibody
33%
Eculizumab
33%
Immunology and Microbiology
Intravenous Immunoglobulin
100%
Immunoglobulin Antibody
100%
Monoclonal Antibody Therapy
100%
Blood Plasma
66%
Immunoglobulin G
33%
Monoclonal Antibody
33%
Autoimmunity
33%
Complement Component C1q
33%
Pharmacokinetics
33%
Respiratory Function
33%
Limb
33%
Muscle
33%
Immunoglobulin
33%
Recombinant Antibody
33%
Cranial Nerve
33%
Eculizumab
33%
Neuroscience
Intravenous Immunoglobulin
100%
Monoclonal Antibody Therapy
100%
Immunoglobulin Antibody
100%
Blood Plasma
66%
Placebo
66%
Immunoglobulin G
33%
Complement Component C1q
33%
Monoclonal Antibody
33%
Randomized Controlled Trial
33%
Pharmacokinetics
33%
Cranial Nerve
33%
Side Effect
33%
Recombinant Antibody
33%
Eculizumab
33%